Semaglutide for Helping Opioid Recovery
NCT06639464 on ClinicalTrials.gov · last registry update 2026-10-13
A small phase 2 — 46 participants, against a typical 110. Due to report 1 September 2027, alongside 40 other tracked readouts that quarter. Primary outcome, as filed: Cue-induced Cravings for Opioids. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Brigham and Women's Hospital
- Sponsor type
- Other
- Enrollment
- 46
- Started
- 2025-06-02
- Primary completion
- 2027-09-01 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-13 | Reporting date moved | 2026-08-31 → 2027-09-01 13 months later |
Primary outcome
Cue-induced Cravings for Opioids
Conditions studied
Opioid Use Disorder
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.